This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
NK Celltech Receives a Series A Round of Funding Worth More Than CNY 100 Million
NK Celltech recently received a Series A round of funding totaling more than CNY 100 million. Huagai Capital led this round of funding, which was followed by CASVC, Unifortune, 呈益资本, Sirius Capital, and QJ Capital.
Jul 01, 2022 03:58 PM
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Exclusive Interview with Ray Hu, Founder and Managing Partner of Blue Lake Capital
Updated 9 hours ago
An Overview of China’s Robotaxi Industry in 2022 for Overseas Investors
Updated 13 hours ago